Myovant_Logo_FullColor_Cropped.png
Myovant Sciences to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
03 juin 2022 06h50 HE | Myovant Sciences, Inc.
BASEL, Switzerland, June 03, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science,...
Myovant and Pfizer Alliance Logo
Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE®
02 juin 2022 06h50 HE | Myovant Sciences, Inc.
BASEL, Switzerland and NEW YORK, June 02, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) accepted...
Myovant_Logo_FullColor_Cropped.png
Myovant Sciences Announces Corporate Updates and Financial Results for Fourth Fiscal Quarter and Fiscal Year Ended March 31, 2022
10 mai 2022 06h55 HE | Myovant Sciences, Inc.
Fiscal year 2021 total revenue of $231.0 million, including net product revenues of $94.3 million; fourth fiscal quarter 2021 total revenues of $57.6 million, including net product revenue of $32.4...
Myovant_Logo_FullColor_Cropped.png
Myovant Sciences and Accord Healthcare, Ltd. Enter into Exclusive License Agreement to Commercialize ORGOVYX® for Advanced Hormone-Sensitive Prostate Cancer in Europe
09 mai 2022 06h30 HE | Myovant Sciences, Inc.
Myovant to receive an upfront payment of $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to $90.5 millionMyovant also eligible to receive...
Myovant and Pfizer Alliance Logo
Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application (sNDA) for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis
06 mai 2022 06h45 HE | Myovant Sciences, Inc.
BASEL, Switzerland, and NEW YORK, May 06, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has...
Myovant_Logo_FullColor_Cropped.png
Myovant Sciences Announces European Commission Approval for ORGOVYX® (relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer
29 avr. 2022 19h10 HE | Myovant Sciences, Inc.
ORGOVYX® is the first and only oral androgen deprivation therapy for advanced hormone-sensitive prostate cancer in EuropeMyovant expects to secure European commercialization partner ahead of...
Myovant_Logo_FullColor_Cropped.png
Myovant Sciences to Host Fourth Fiscal Quarter and Fiscal Year 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on May 10, 2022
26 avr. 2022 08h30 HE | Myovant Sciences, Inc.
BASEL, Switzerland, April 26, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced it will host a webcast and conference call to discuss corporate updates and financial results for...
Myovant and Pfizer Alliance Logo
Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated with Endometriosis
12 avr. 2022 00h00 HE | Myovant Sciences, Inc.
BASEL, Switzerland and NEW YORK, April 12, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer (NYSE: PFE) announced today an update on the Supplemental New Drug Application (sNDA) for...
Myovant_Logo_FullColor_Cropped.png
Myovant Sciences Receives Positive CHMP Opinion for ORGOVYX® (relugolix) for the Treatment of Advanced Prostate Cancer
25 févr. 2022 09h00 HE | Myovant Sciences, Inc.
CHMP opinion recommending approval based on data from the global Phase 3 HERO study If approved, ORGOVYX® would be the first and only oral androgen deprivation therapy for advanced hormone-sensitive...
Myovant_Logo_FullColor_Cropped.png
Myovant Sciences to Present at Upcoming Investor Conferences
07 févr. 2022 08h30 HE | Myovant Sciences, Inc.
BASEL, Switzerland, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, Chief...